Back to top
more

ResMed (RMD)

(Delayed Data from NYSE)

$238.75 USD

238.75
1,334,422

-5.37 (-2.20%)

Updated Oct 1, 2024 04:00 PM ET

After-Market: $238.78 +0.03 (0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 27% (68 out of 251)

Industry: Medical - Products

Better trading starts here.

Zacks News

Here's How Much a $1000 Investment in ResMed Made 10 Years Ago Would Be Worth Today

Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.

CVS Health (CVS) Expands Food and Beverage Line With New Launch

CVS Health's (CVS) Well Market brand offers a blend of mouthwatering flavors and nutritious options, expertly crafted and taste-tested by food enthusiasts.

Bruker (BRKR) Gains Market Share on Innovation Amid Macro Woes

Bruker's (BRKR) BSI Nano business is seeing robust revenue growth across its end markets, including academic, government, industrial and semiconductor metrology.

Here's Why You Should Buy Haemonetics (HAE) Stock Now

Strong prospects of the Plasma franchise and favorable solvency bode well for Haemonetics (HAE).

Medtronic's (MDT) MiniMed 780G AID System Wins New Accolade

Medtronic's (MDT) MiniMed 780G system gets recognized among Fast Company's 2024 World Changing Ideas.

Veracyte (VCYT) Up 6% Since Last Earnings: Will it Continue?

Investors are optimistic about Veracyte (VCYT) led by strength in the testing business and upbeat guidance.

Wall Street Analysts See ResMed (RMD) as a Buy: Should You Invest?

According to the average brokerage recommendation (ABR), one should invest in ResMed (RMD). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?

Here's Why Investors Should Buy ResMed (RMD) Stock Now

Investors are optimistic about ResMed's (RMD) potential in digital health and expansion in the international market.

Boston Scientific (BSX) mCRM System Study Outcome Favorable

Boston Scientific (BSX) mCRM System is designed to communicate wirelessly and coordinate painless intracardiac anti-tachycardia pacing (ATP) therapy.

Haemonetics' (HAE) Hospital & Plasma Segments, Innovation Aid

Haemonetics' (HAE) hospital portfolio is evolving and helping to create new opportunities for growth and diversification.

Maravai (MRVI) Advances in RNA Research With New Collaboration

Per Maravai LifeSciences (MRVI) management, this development by TriLink is set to advance nucleic acid-based therapies.

Haemonetics (HAE) Stock Up 10.9% YTD: Will the Rally Continue?

Investors are optimistic about Haemonetics (HAE) led by its strategic focus on establishing leading positions in high-growth markets to generate solid financial returns.

What Makes ResMed (RMD) a New Strong Buy Stock

ResMed (RMD) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Align Technology (ALGN) Gains From Innovation, Global Expansion

In the United States, Align Technology (ALGN) is focused on reaching young adults as well as teens and their parents through famous athletes, influencers and fashion designers.

Prestige Consumer (PBH) Q4 Earnings Miss, Operating Margin Falls

Prestige Consumer's (PBH) Q4 business suffers from supply chain pressure that impacts its ability to fulfill retailer orders.

Labcorp (LH) to Assess Preeclampsia Risk With New Test

Labcorp's (LH) new first-trimester test is the latest addition to its dedication to improving women's health.

Here's Why You Should Retain Henry Schein (HSIC) Stock for Now

Investors are optimistic about Henry Schein (HSIC), owing to strategic acquisitions and potential in Henry Schein One.

Here is Why Growth Investors Should Buy ResMed (RMD) Now

ResMed (RMD) possesses solid growth attributes, which could help it handily outperform the market.

Here's Why You Should Buy Align Technology (ALGN) Stock Now

Investors are optimistic about Align Technology (ALGN) led by expansion in new geographies and upbeat guidance.

QIAGEN's (QGEN) QCI Interpret Gets European IVDR Certification

QIAGEN's (QGEN) Clinical Insight Interpret is the first NGS interpretation platform approved by IVDR for use in cancer and hereditary applications.

Why ResMed (RMD) is a Top Growth Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Henry Schein (HSIC) Extends Partnership With Special Olympics

Henry Schein's (HSIC) extended collaboration with Special Olympics is likely to promote wellness and health education for athletes with ID around the world.

Zacks.com featured highlights BellRing Brands, ResMed, NVIDIA and Transdigm

BellRing Brands, ResMed, NVIDIA and Transdigm have been highlighted in this Screen of The Week article.

Alcon (ALC) Q1 Earnings Surpass Estimates, Margins Expand

Alcon's (ALC) Q1 results reflect substantial growth in its franchises on the back of healthy markets.

Boston Scientific (BSX) Gains From MedSurg Growth & Buyouts

Within Neuromodulation, Boston Scientific's pain business is consistently gaining traction, banking on strength in the spinal cord stimulation (SCS) business.